New analyses suggest Alzheon’s therapy may pro

The startup is betting that the future of longev

Eisai and Biogen presented data at the Alzheimer’s Association International Conference 2026 in London showing that a lecanemab subcutaneous autoinjector (LEQEMBI) produced exposure, efficacy and safety comparable to the approved intravenous initiation regimen in people with early Alzheimer’s disease. According to the company, once-weekly 500 mg subcutaneous administration demonstrated bioequivalence to the IV initiation regimen (10 mg/kg every two weeks) with an exposure ratio of 104% (90% confidence interval 99.1%–109%) and consistent exposure across body weight quartiles. The companies claim that amyloid reduction measured by PET, clinical efficacy on CDR-SB and incidence of ARIA-E were driven by lecanemab exposure rather than route of administration. Safety findings were generally consistent with the IV formulation; injection-related reactions were mostly localized, predicted ARIA-E incidence was similar, and anti-drug antibodies occurred in 1.4% of patients with no neutralizing antibodies observed. Early clinical and real-world data from two U.S. centers indicated slower cognitive decline on CDR-SB over 36 months in a 28-patient cohort versus a matched natural history cohort, and 10 of 11 evaluable patients in a separate series improved or remained stable on MMSE after maintenance therapy. The company reports high patient and care partner satisfaction and notes flexibility to switch between IV and…

Cognito Therapeutics presented exploratory cerebr

At the Alzheimer’s Association International Co

NeuroTherapia will present data from its recently

Indiana University and PharmatrophiX presented a

Aeon welcomed the establishment of the Dubai Long

Eisai presented data at the Alzheimer’s Associa

The New England Journal of Medicine published a p

New study shows long-assumed irreversible AGEs c

Positive Phase 3 results hint that the next obes

Chinese biotech’s universal CAR-T therapy secu

As experimental cell therapy heads to BIOCHINA,

Viz.ai announced a collaboration with Cortechs.

AB Science announced on 10 July 2026 that it will

Serina Therapeutics announced completion of senti

MetaVia reported that all enrolled active patient

Rani Therapeutics has entered a research and deve

NorthStrive Biosciences, a PMGC Holdings Inc.

A4LI’s Brenda Eap highlights a turning point f

A4LI’s Brenda Eap highlights a turning point f

Maryland is asking whether governments should pr

Maryland is asking whether governments should pr

French biotech pushes a single brain-protecting

Kenai Therapeutics has completed enrollment in th

FibroBiologics completed manufacturing of a third

Elysium reported results from an open-label pilot

Insilico Medicine, a generative AI-driven clinica

Amprion, headquartered in San Diego, announced on

Standard disease frameworks are meeting their ma

Five-year renewal backs new drug discovery proje

A fresh analyst upgrade and encouraging clinical

Haut.

Alterity Therapeutics received official End-of-Ph

Catalent and Nanoscope Therapeutics expanded thei

RoslinCT and BlueRock Therapeutics have entered a

Aptorum Group Limited and DiamiR Biosciences anno

The seventh Longevity Investors Conference bring

Year-long study shows people with mild Alzheimer

Company to spotlight clinical progress on immune

Theriva Biologics announced that the Spanish Agen

Helix announced a multi-year agreement with Astra

Insilico has initiated a Phase III clinical trial

Annovis Bio Inc.

Kailera reported positive topline results from tw

As South Korea’s peptide market surges, partne

BioAge has begun iPhase 2 QUELL-CV trial, testin

Insilico’s rentosertib enters late-stage testi

Eyepoint Pharmaceuticals will participate in the